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50 The Journal of Thoracic and Cardiobjective: Using a national cancer registry, we determined the postoperative sur-
ival of patients with stage IA non–small cell lung cancer in the United States from
988 to 1997 and identified factors that affect survival.
ethods: Within the Surveillance, Epidemiology, and End Result Program data-
ase, 10,761 patients were identified as having stage IA non–small cell lung cancer
nd underwent curative surgical resection from 1988 to 1997. Univariate analyses
ere performed by the log–rank test to determine predictors of survival, and
ultivariable analysis was performed by a Cox regression model.
esults: Overall 5-year survival was 58%. On univariate analysis, tumor size,
ender, age, and extent of resection were significant predictors of survival. Five-year
urvival of patients with tumors 2.1 to 3.0 cm was lower than that for patients with
umors 2.0 cm or smaller: 55% versus 60% (P  .0001). Men faired significantly
orse than women, with a 5-year survival of 53% versus 63% (P .0001). Patients
lder than the median age of 67 years had worse 5-year survival than had those
nder the median age: 52% versus 65% (P  .0001). Patients undergoing sublobar
esections showed poorer 5-year survival than patients undergoing anatomic resec-
ions: 44% versus 61% (P  .0001). On multivariable analysis with a Cox regres-
ion model, all 4 variables remained statistically significant.
onclusion: The survival of patients with stage IA non–small cell lung cancer within
he United States is significantly worse than survival reported from single-institution
tudies. This study identifies 4 factors that may affect survival in resected stage IA
on–small cell lung cancer: tumor size, gender, age, and extent of resection.
ung cancer is the leading cause of cancer deaths among both men and women
in the United States. There are approximately 170,000 new cases of lung
cancer annually and 160,000 deaths annually from lung cancer.1 Fewer than
0% of patients diagnosed with lung cancer are candidates for surgical resection. Of
hose patients undergoing surgical resection, patients with stage IA disease (T1 N0
0) have the best chance of cure. A multi-institutional study reported a 67% 5-year
urvival for patients undergoing resection for stage IA disease.2 In contrast, single-
nstitution studies have generally reported better 5-year survivals, ranging from 65%
3-8o 90%. There are no studies detailing the survival of patients with stage IA
vascular Surgery ● October 2007
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TSisease across a large population base, including both com-
unity hospitals and academic centers.
Within the stage IA designation, there may be patient
haracteristics that influence long-term survival. A number
f investigators have reported that tumor size influences
urvival within the stage IA classification.5,8-12 Others have
ound no correlation between size and survival within stage
A.13,14 Female gender has also been found in several stud-
es to confer a survival advantage over male patients with
on–small cell lung cancer (NSCLC) across all stages.15-17
n several studies, patient age has been found to be a
redictor of postoperative survival in stage I and II
SCLC.18,19 The issue of whether a sublobar resection
esults in worse long-term survival than that of anatomic
esection has been studied by numerous investigators. Some
ingle-institution, nonrandomized, retrospective studies
ave found poorer survival with sublobar resections,5,9
hereas other single-institution, nonrandomized studies of
tage IA NSCLC showed no difference in survival between
obectomy and sublobar resections.6,7 A prospective, ran-
omized, multi-institutional trial by the Lung Cancer Study
roup20 reported statistically significant survival advantage
n favor of the lobectomy group (all causes of death, P 
088; P value for significance level set at 0.1 in study
esign). The results were later revised but did not change
he conclusions of the study.21
This study was conducted to determine the survival of
atients with stage IA NSCLC who underwent curative resec-
ion from 1988 to 1997 across a broad population base in the
nited States using the Surveillance, Epidemiology, and End
esult (SEER) database. Furthermore, this study individu-
lly examines the impact of tumor size, gender, patient age,
nd extent of surgical resection on survival within this
ohort. Finally, these prognostic factors are combined in a
ultivariable Cox proportional hazards model to determine
hich factors remain independent predictors of survival.
aterials and Methods
he SEER Program is a database of cancer incidence and survival
n the United States sponsored by the National Cancer Institute.
rom its inception in 1973, the program has collected clinicopath-
logic data from population-based cancer registries and currently
overs 26% of the US population. It is estimated that the SEER
rogram captures 98% of all cancer cases in these geographic
reas.22 The cancer registries include most of California, Connect-
cut, Iowa, New Mexico, Utah, Hawaii, the Detroit, Atlanta, and
Abbreviations and Acronyms
NSCLC non–small cell lung cancer
SEER  Surveillance, Epidemiology, and End Result
(database)eattle metropolitan areas, and parts of Georgia and Arizona. The M
The Journal of Thoracicntire state of California, New Jersey, Kentucky, and Louisiana
ere added in 2001. From the SEER registry spanning the years
973 to 2000, we identified all cases of lung cancer (tumor site
ode 34.0 to 34.9), which totaled 414,867 patients. Additionally,
sing the International Classification of Diseases for Oncology-2
orphology codes, we selected only cases of NSCLC, eliminating
ll patients with small cell carcinoma, neuroendocrine tumor,
esothelioma, carcinoid tumor, and sarcoma.
Starting in 1988, detailed stage and extent of disease data were
dded to the SEER registry; therefore, we confined our analysis to
988 and later. The coding for extent of surgery changed after
997; therefore, we ended our analysis with the year 1997. We
estricted the analysis to the following criteria: patients with diag-
ostic confirmation of NSCLC (SEER confirm code 4); patients
ho underwent curative surgical resection (SEER reason
ode  0); tumors less than or equal to 3.0 cm (SEER tumor
ize code  30); absence of lymph node metastasis (SEER
ymph node code  0); and absence of visceral pleural involve-
ent or location within 2 cm of the carina or distant metastasis
SEER extension code). We identified 10,761 patients with T1 N0
0 disease who underwent curative surgical resection. We defined
urative surgical resection as any operation other than local tumor
estruction or excision; thus, we included patients undergoing
edge resections and segmentectomies.
The SEER database contains a variety of patient demographic
ata, cancer staging data, and some treatment data. We made an a
riori decision to investigate tumor size, gender, age, and extent of
esection for effect on survival. We partitioned the patients by
umor size (0.1–2.0 cm or 2.1–3.0 cm), age (above or below the
edian of 67 years), and extent of resection (sublobar resection vs
obectomy or greater, SEER site-specific surgery code). For the
nivariate analyses, we constructed survival curves using the
aplan–Meier method and compared survival between groups
sing log–rank tests. Multivariable analysis was performed by
onstructing a Cox proportional hazards model using the signifi-
ant factors (P  .05) from the univariate analyses: tumor size,
ender, age, and extent of resection. The analyses were performed
ith the SASv8 statistical software program (SAS Institute, Inc,
ary, NC).
esults
here were 10,761 patients who met the inclusion criteria
or the study: stage IA NSCLC undergoing curative resec-
ion. The 1-, 3-, and 5-year survival rates for the entire
roup were 90.2%, 71.5%, and 57.8%, respectively. Table 1
hows the 1- to 5-year survivals of the entire SEER group
ompared with the survival data reported by Mountain.2
one of the 95% confidence intervals for the SEER group
ontain the survivals reported by Mountain, which suggests
urvival is worse in our study. Moreover, during the period
f this analysis, 1988 to 1997, we did not observe a trend
oward improvement in survival by year of diagnosis (log–
ank test; P  .69).
The results of the univariate analyses examining the
ffect of tumor size, gender, age, and extent of resection are
ummarized in Table 2, and the corresponding Kaplan–
eier survival plots are shown in Figure 1. We examined
and Cardiovascular Surgery ● Volume 134, Number 4 851
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G
TShe effect of tumor size on survival, using tumor size as a
inear continuous variable. The size of the tumor signifi-
antly affected survival with a hazard ratio of death per
illimeter tumor size of 1.014 (P  .0001). To simplify
nterpretation, we dichotomized tumor size into 0.1 to 2.0
m and 2.1 to 3.0 cm. There were 6161 patients with tumors
.1 to 2.0 cm in size and 4600 patients with tumors 2.1 to
.0 cm in size. Patients in the small tumor group had better
-year survival than patients with larger tumors: 60.3%
ersus 54.5% (log–rank test; P  .0001). The hazard ratio
or death for having a tumor 2.1 to 3.0 cm compared with a
umor 0.1 to 2.0 cm is 1.183. Within the small tumor group,
e compared patients with tumors from 0.1 to 1.0 cm to
atients with tumors 1.1 to 2.0 cm. There was no difference
n survival (log–rank test; P .78); therefore, these patients
ere grouped together.
There were 5320 women and 5441 men in the study
roup (Table 2). Examining the effect of gender on survival,
e found women had superior 5-year survival compared
ith men: 63.0% versus 52.8% (log–rank test; P  .0001).
he hazard ratio of death for being male was 1.328. On
verage, women had slightly smaller tumors (1.98 cm vs
ABLE 1. Survival using the Kaplan–Meier method with
5% confidence intervals as compared with survival re-
orted by Mountain2
Mountain (n  511) SEER (n  10,761)
% % 95% CI (%)
y 94 90.2 89.6-90.8
y 86 80.3 79.5-81.1
y 80 71.5 70.6-72.4
y 73 64.3 63.4-65.2
y 76 57.8 56.8-58.8
I, Confidence interval.
ABLE 2. Univariate analysis
atient characteristic n 1 y (%) 2 y (%)
ize of tumor
0.1-2.0 cm 6161 91.4 82.0
2.1-2.9 cm 4600 88.5 78.1
ender
Female 5320 92.4 83.6
Male 5441 88.0 77.1
ge
67 y 4936 92.7 84.4
67 y 5825 88.0 76.9
xtent of resection
Lobe  8527 90.5 82.1
Sublobar 2234 88.7 73.4Kaplan–Meier survival estimates. †Log–rank test. ‡Cox proportional hazard mo
52 The Journal of Thoracic and Cardiovascular Surgery ● Octo.05 cm) and were younger than men (median age 67 years
s 68 years).
The effect of age on survival after surgical resection was
xamined (Table 2). We performed the analysis using age as
linear continuous variable and found it to be statistically
ignificant (hazard ratio 1.034; P  .0001; results not
hown). For ease of interpretation, we dichotomized age by
he median age 67 years. There were 4936 patients under the
edian age of 67 and 5825 patients aged 67 or greater.
atients under the median age had better 5-year survival
han patients over the median: 65.2% versus 51.5% (log–
ank test; P  .0001). The hazard ratio for death for being
n the older age group was 1.664. On average, the older
atients had slightly larger tumors than the younger pa-
ients: 1.97 cm versus 2.06 cm.
We analyzed the survival of patients who underwent
ublobar resection (wedge resection and segmentectomy)
ompared with patients who underwent lobectomy (or
reater resection). Of the 10,761 patients in the study group,
527 patients underwent lobectomy or greater resections,
nd 2234 patients underwent sublobar resections (Table 2).
he lobectomy group had better 5-year survival than the
ublobar group: 61.4% versus 44.0% (log–rank test; P 
0001). The hazard ratio for death for having a sublobar
esection was 1.621. On average, patients undergoing lo-
ectomy had larger tumors (2.07 cm vs 1.82 cm) but were
ounger (median age 67 vs 69) than the patients undergoing
ublobar resections. These data need to be interpreted with
aution inasmuch as the SEER database does not contain
omorbidity data or pulmonary function tests, which may
ave influenced the choice of operation by the treating
hysician. Therefore, the sublobar group may have risk
actors, not contained within this database, that influence
heir long-term survival after resection. Additionally, pa-
ients with sublobar resections may not have undergone
Survival*
%) 4 y (%) 5 y (%) P value† Hazard ratio‡
9 67.0 60.3
3 60.8 54.5 .0001 1.183
6 69.1 63.0
5 59.7 52.8 .0001 1.328
5 71.0 65.2
5 58.7 51.5 .0001 1.664
0 67.5 61.4
0 52.2 44.0 .0001 1.6213 y (
73.
68.
75.
67.
77.
66.
74.
62.del containing 1 variable.
ber 2007
mt
i
h
t
r
T
a
t
t
s
u
s
l
(
s
a
r
t
t
l
g
e
t
f
T
ith p
T
v
h
M
T
A
S
C
Chang et al General Thoracic Surgery
G
TSediastinal or hilar lymph node dissection and, therefore,
he stage may be underestimated.
To determine whether all 4 variables remain significant
n a multivariable analysis, we created a Cox proportional
azards model with the 4 significant variables: gender,
umor size, age, and extent of resection. All 4 variables
emained statistically significant with P values  .0001.
he hazard ratios, 95% confidence intervals, and P values
re summarized in Table 3.
Figure 1. A, Kaplan–Meier survival estimates comparin
tumors 2.1 to 3.0 cm. B, Kaplan–Meier survival estimat
estimates comparing patients younger than 67 years ol
estimates comparing patients undergoing lobectomy w
ABLE 3. Hazard ratios, 95% confidence intervals, and P
alues for the 4 variables entered into the Cox proportional
azards model
Hazard ratio 95% CI P value
ale vs female 1.335 1.261, 1.406 .0001
umor 2–3 cm vs 0–2 cm 1.202 1.140, 1.267 .0001
ge 67 y vs 67 y 1.595 1.512, 1.683 .0001
ublobar resection vs lobe 1.611 1.517, 1.710 .0001eI, Confidence interval.
The Journal of ThoracicTo address the issue of understaging the disease in pa-
ients who underwent sublobar resections, we investigated
he percentage of patients who had at least 1 lymph node
ampled during their curative resection. Of the patients
ndergoing lobectomy, 89% had at least 1 lymph node
ubmitted for pathologic examination, whereas in the sub-
obar group, only 39% had at least 1 lymph node submitted
2 test; P  .0001). When a dichotomous variable repre-
enting the number of lymph nodes examined (0 or 1) was
dded to the Cox proportional hazards model, all 4 variables
emained statistically significant (Table 4). With the addi-
ion of the lymph node variable, the hazard ratio for gender,
umor size, and age did not change, indicating that the
ymph node variable is not a confounder of the effect of
ender, tumor size, and age. However, the hazard ratio for
xtent of resection decreased by 10% with the addition of
he lymph node variable, suggesting this variable is a con-
ounder of the effect on survival of extent of resection.
herefore, the lymph node variable explains some of the
tients having tumors 0.1 to 2.0 cm with patients having
mparing women with men. C, Kaplan–Meier survival
h patients 67 years or older. D, Kaplan–Meier survival
atients undergoing sublobar resection.g pa
es co
d witffect of extent of resection on survival; however, even with
and Cardiovascular Surgery ● Volume 134, Number 4 853
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G
TShe lymph node variable in the model, extent of resection
emains statistically significant.
Of the 10,761 patients, we compared two subgroups to
nvestigate the two extremes of survival within our cohort of
atients. There were 1201 favorable prognosis patients who
ere female, had tumors 2.0 cm or less, were less than 67
ears old, and underwent a lobectomy or greater resection.
n contrast, there were 251 poor prognosis patients who
ere male, had tumors between 2.1 and 3.0 cm, were 67
ears old or older, and underwent a sublobar resection. In a
nivariate analysis comparing these two groups, the 5-year
urvival of the favorable prognosis subgroup was 74.3%
ompared with 29.7% for the poor prognosis subgroup
log–rank test; P  .001). The hazard ratio of death for
eing in the poor prognosis group compared with the fa-
orable prognosis group is 4.047.
iscussion
his study examines the survival of patients with stage IA
isease within a large percentage of the US population and
ncludes the largest cohort of patients with stage IA NSCLC
reated with curative surgical resection in the literature.
hese data provide a snapshot of the survival that is being
chieved across the United States, rather than at single
pecialized institutions. We investigated patient character-
stics that would predict poor survival within this group. We
ound tumors 2.1 to 3.0 cm, age greater than or equal to the
edian of 67 years, male gender, and sublobar resection to
e statistically significant predictors of poor survival. The
azard ratio is largest for age and extent of resection (1.664
nd 1.621, respectively) and smallest for size of tumor
1.183). Analysis with a Cox proportional hazards model
howed all 4 predictors remained independent predictors of
urvival.
Curative surgical resection is the most effective therapy
or patients with stage IA NSCLC. Most series report 5-year
urvivals between 60% and 90%, with single-institution
esults generally much better than multi-institution studies.
ountain2 published a large series evaluating the survival
f patients after surgical resection, using the revised staging
ABLE 4. Hazard ratios, 95% confidence intervals, and
values for the 5 variables entered into the Cox propor-
ional hazards model
Hazard ratio 95% CI P value
ale vs female 1.336 1.268, 1.407 .0001
umor 2–3 cm vs 0–2 cm 1.208 1.114, 1.273 .0001
ge 67 y vs 67 y 1.587 1.504, 1.674 .0001
ublobar resection vs lobe 1.452 1.354, 1.557 .0001
ero nodes sampled 1.233 1.150, 1.322 .001
I, Confidence interval.ystem. In Mountain’s series there were 511 patients with e
54 The Journal of Thoracic and Cardiovascular Surgery ● Octoathologic stage IA NSCLC. Survival was found to be 67%
t 5 years.2 The overall 5-year survival of our cohort of
atients is 57.8%, which was worse than we expected. This
ifference may be explained by understaging. The data for
he Mountain’s report came from The M. D. Anderson
ancer Center and the institutions of the Lung Cancer Study
roup, and the pathologic slides were reviewed at a single
athology center. Staging in this study was likely more
ccurate and more uniform than in our study, despite the
atients being treated one decade earlier than the patients in
ur study. The SEER data are complied from multiple state
ancer registries, which in turn contain a compilation of
ospital pathology reports. The heterogeneity of these data
ources and heterogeneity of clinical practice across thou-
ands of physicians likely results in understaging and would
ead to poorer long-term survival.
A number of investigators have examined tumor size,
ender, age, and extent of resection as predictors of survival
n patients with NSCLC. This study examines these predic-
ors individually and together in a multivariable model in
atients with stage IA NSCLC across a broad population
atabase. We found all 4 factors to be statistically signifi-
ant predictors of survival, both individually and in the
ultivariable model. Given the potential of understaging
ithin this database, the results need to be interpreted with
aution. However, the analyses of the gender and age dif-
erences are likely to be valid even if the disease is under-
taged. We would predict that understaging would be as
ommon in men as in women and in patients older and
ounger than 67 years. Therefore, we conclude that female
ender and younger age are independent predictors of im-
roved long-term survival.
The analysis of tumor size and extent of resection are more
ikely to be affected by understaging than by gender and age.
arger tumors are more likely to have regional or distant
etastasis; therefore, the patients in the 2.0- to 3.0-cm tumor
roup are more likely to harbor occult metastasis. However,
ven in carefully performed single-institution studies where
he patients’ tumors are thoroughly and uniformly staged,
nvestigators have found a difference in survival between
mall T1 and large T1 tumors.5,8-10,12
In an attempt to address the issue of understaging in
atients who received sublobar resections, we added a di-
hotomous variable representing number of lymph nodes
ubmitted for pathologic examination. Not surprisingly,
9% of the lobectomy patients had at least 1 lymph node
ubmitted, whereas only 39% of the sublobar patients had at
east 1 lymph node submitted (2 test; P  .0001). When
his lymph node variable is added to the Cox proportional
azards model, the hazard ratio of extent of resection de-
reased but remained statistically significant, suggesting
hat lymph node examined is a confounder of the effect of
xtent of resection on survival. Because the SEER database
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G
TSoes not contain comorbidity data, there may be other
nmeasured confounders that may reduce the effect of ex-
ent of surgery on survival.
We showed that patients with all 4 negative prognostic
actors have very low 5-year survival compared with pa-
ients with all 4 positive prognostic factors. These results
ighlight the great disparity in survival even within the
tage IA designation. Patients in the poor prognosis sub-
roup may benefit from consideration of alternate forms of
herapy. Furthermore, patients in this subgroup would be a
ogical choice in whom novel nonsurgical primary therapy
r adjuvant forms of therapy could be studied.
The limitations of this study are in the reliability of the
taging data and lack of comorbidity data. Since the patho-
ogic data are compiled from reports from hundreds of
ospitals, there is a lack of uniformity in reporting and
nterpretation. Furthermore, there is no uniformity in how
nvasively the disease is staged—choice of radiographic
taging studies, decision to perform mediastinoscopy, thor-
ughness of mediastinal lymph node dissection, and com-
leteness of pathologic examination of the surgical speci-
en. Therefore, it is likely that a higher percentage of the
atients in this study have understaged disease, compared
ith small single-institution studies. Additionally, without
atient comorbidity data, we have no method to look for
ther significant predictors of survival, nor can we look for
ignificant confounders of our 4 significant variables. How-
ver, this study does provide a snapshot of postoperative
urvival of patients with NSCLC staged as IA across the
nited States at the community level during a contemporary
0-year time period.
In the future, investigators will continue to refine the
NM staging system and identify important patient charac-
eristics to more precisely determine prognosis and identify
atients at risk for poor outcome. Patients in the poor
utcome subgroups would be logical candidates for adju-
ant therapy or alternatives forms of therapy.
onclusions
n the largest series of surgically treated patients with stage
A NSCLC in the literature compiled from a national cancer
egistry, we found that tumor size between 2.1 and 3.0 cm,
ale gender, age greater than 67 years, and sublobar resec-
ion are predictors of poor 5-year survival. These results
ere statistically significant in both univariate and multiva-
iable analyses. Patients with all 4 negative predictors have
ery poor 5-year survival.
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G
TSiscussion
r Alex G. Little (Dayton, Ohio). I think we would all agree that
ny collection of this large number of patients deserves to be
nalyzed and thought about carefully. That said, I am going to get
o three areas in which I have some questions. One is to make a
tatement with which I know you agree because of having had the
pportunity to read your manuscript and your identification of the
imitations. The statement is that the validity of any clinical review
f patients with IA disease really is dependent on the accuracy of
he staging process that classified those patients. That being said,
do not think the concern of some patients with actual stage III or
I disease being included weakens your conclusions, because pre-
umably on a random basis the patients would have been evenly
istributed. However, I think it really undermines to the point of
egating any observations about long-term survival of patients
ith IA disease because we just do not know that this is really a
lean collection of patients with stage IA disease. Would you
omment on that, please?
Dr Chang. Yes, I agree. If you look at the entire cohort, it is
ifficult to reach the conclusion that 5-year survival is 58% be-
ause of this issue of understaging. I think some of the predictors
e looked at probably are valid. For example, there is no reason to
hink that the men were understaged more than the women, so that
ifference probably remains valid even if the numbers themselves
ay be slightly higher in a carefully staged population of patients.
Dr Little. With that in mind, you might think about modifying
our manuscript and not being too declarative about the survival of
ust patients with IA disease.
The second question has to do with the issue of the wedge
esections. There are wedge resections and then there are wedge
esections. Do you have any information about whether or not
here were frozen section analyses done of the margins? Do we
eally know that those were “good” wedge resections?
Dr Chang. No, the database does not contain information on
argin status.
Dr Little. I do not think any of us really wants to stoutly defend
hat being the ideal choice for lung cancer; nonetheless, the results
ight have been better had those wedge resections been quality-
ontrolled.
Dr Chang. That is absolutely correct.
Dr Little. Finally, there is an old saying: A difference to be a
ifference must make a difference. What difference does it make
o us as clinicians to have this information? Would you suggest
hat patients with some number of these negative prognostic fac-
ors should be treated differently—not operated on, operated on
ith smaller operations, receive multimodality therapy, either ad-
uvant therapy or neoadjuvant? What can we take home from this
hat will affect our patient care?
Dr Chang. We do not suggest that these results are the best that
re achievable. Looking at carefully controlled and staged single-
nstitution studies would give us a better idea of what is the best
ossible practice. What this does show is the current state within
he United States of patients who are deemed to have stage IA
isease, and I think these results raise the issue that many patients
re probably not being staged properly. I think understaging ac-
ounts mostly for the difference in survival between this study and
ingle-institution studies.Dr Little. I agree. Thank you. S
56 The Journal of Thoracic and Cardiovascular Surgery ● OctoDr Nasser K. Altorki (New York, NY). I enjoyed your presen-
ation.
I have two questions. First, have you had an opportunity to look
t the effect of cell type, squamous versus nonsquamous histologic
ypes? Second, you have presented us, I presume, with overall
urvival/all-cause mortality. Have you had an opportunity to look
t lung cancer–specific deaths?
Dr Chang. Thank you for your question. The data on cell type
re available in the SEER database. There were about 42% ade-
ocarcinomas and about 25% squamous cell carcinomas. How-
ver, we did not look at the impact of histology on survival. With
egard to all-cause mortality, there is a variable within the database
ndicating the cause of death, but we believed that this was
robably a fairly unreliable variable because it is abstracted from
eath certificates. Often, the cause of death on a death certificate is
isted as cardiac arrest or multisystem organ failure without any
utopsy data. We thought that that was probably a fairly unreliable
ay to look at survival. Therefore, you are absolutely correct; this
s all-cause survival.
Dr Todd Demmy (Buffalo, NY). Regarding age, why did you
se 67 as your age dichotomizing cut point? Did you look at the
opulation of early emerging lung cancer? There have been reports
f patients presenting in their 40s and 50s with lung cancer having
worse biological disease. Did you look at your data for the young
roup of patients presenting with lung cancer?
Dr Chang. Thank you for your question, Dr Demmy. We did
ot specifically look at the younger populations. We did analyze
ge as a continuous variable, and age was a significant predictor of
urvival. We chose to dichotomize age to make interpretation of
he results easier. But we did not go through and look at multiple
uintiles and specifically focus on the younger patients. However,
ou are correct in that with a cohort of this size, we do have the
ower to examine survival in the very young patients. This addi-
ional analysis would be very worthwhile.
Dr David H. Harpole, Jr (Durham, NC). I know that the
EER data are localized. Did you look at any volume determinants
ersus survival? In other words, did you look in the SEER set to
ee the sites that were low volume versus high volume and see
hether that translated into a long-term survival difference? Along
he same vein, I think some SEER data have universal physician
dentification numbers (UPIN). I do not know how much of that
nformation you have. Could you drill it down to type of surgeon?
e have thought about doing this in administrative databases
here you can look at the type of surgery done by the UPIN-
erived surgeon to see whether you could separate actually who
id the operation, because you may find that some of these wedges
ere actually not high comorbid but maybe were not necessarily
one by a thoracic surgeon. That could be interesting data as well
f you are able to get that.
Dr Chang. Thank you for your question and comment. I am
ot aware that the UPINs are available in the SEER database. I do
now that the hospital where the procedure was performed is not
vailable in the SEER database. Hospital identification information
s available in the SEER–Medicare database, which we have not
ooked at. The downside of the SEER–included Medicare data-
ase, of course, is that patients under age 65 are not in the
EER–Medicare database.
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